Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Sanderzon Mar 30, 2018 3:24pm
164 Views
Post# 27808763

bad investment?

bad investment?guys, people on thi board have been saying for years that this will go up higher, longs will be rewarded, etc. etc.  and I see this talk time and time and time again on other oards.   I'm sure in some stocks, yes you be patient and you can make a lot of money.  but I dunno about this one..  Just because WE know this drug is a breakthrough, doesn't mean the market looks at it that way.  Look at the charts, it's been years since this was in the 0.50's  UNTIL recently.    so it made a spike up to .79, now settling into the 40's, maybe 50's if we're lucky.  So then what?  I don't think this will go to over $1 anytime soon or even in a coule years. otherwise, why hasn't it done that by now?  why hasn't it done that in the past?

I'm not trying to knock this, it seems like a good company and good development. but the MARKET... it's the MARKET that I'm knocking.  this should be valued higher but it's not.
Bullboard Posts